公开(公告)号：WO2007117465A2

公开(公告)日：2007-10-18

申请号：PCT/US2007/008307

申请日：2007-04-02

Applicant: ABBOTT LABORATORIES ,  ERICSSON, Anna M. ,  BURCHAT, Andrew ,  FRANK, Kristine E. ,  CALDERWOOD, David J. ,  ABBOTT, Lily K. ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  CUSACK, Kevin P. ,  DIXON, Richard W. ,  GORDON, Thomas D. ,  MULLEN, Kelly D. ,  TALANIAN, Robert V. ,  WU, Xiaoyun ,  ZHANG, Xiaolei ,  WANG, Lu X. ,  LI, Biqin ,  BARBERIS, Claude E. ,  WISHART, Neil

Inventor： ERICSSON, Anna M. ,  BURCHAT, Andrew ,  FRANK, Kristine E. ,  CALDERWOOD, David J. ,  ABBOTT, Lily K. ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  CUSACK, Kevin P. ,  DIXON, Richard W. ,  GORDON, Thomas D. ,  MULLEN, Kelly D. ,  TALANIAN, Robert V. ,  WU, Xiaoyun ,  ZHANG, Xiaolei ,  WANG, Lu X. ,  LI, Biqin ,  BARBERIS, Claude E. ,  WISHART, Neil

IPC: A61K31/5377

CPC classification number: C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/04 ,  C07D409/14

Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Abstract translation: 式（I）的新型化合物或其药学上可接受的盐，前体药物和式（I）的生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。

公开(公告)号：WO2007005608A2

公开(公告)日：2007-01-11

申请号：PCT/US2006/025584

申请日：2006-06-29

Applicant: ABBOTT LABORATORIES ,  LACY, Susan E. ,  FUNG, Emma ,  BELK, Jonathan P. ,  DIXON, Richard W. ,  ROGUSKA, Michael ,  HINTON, Paul R. ,  KUMAR, Shankar

Inventor： LACY, Susan E. ,  FUNG, Emma ,  BELK, Jonathan P. ,  DIXON, Richard W. ,  ROGUSKA, Michael ,  HINTON, Paul R. ,  KUMAR, Shankar

IPC: C07K14/715

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

Abstract translation: 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。

公开(公告)号：WO2008118485A1

公开(公告)日：2008-10-02

申请号：PCT/US2008/004007

申请日：2008-03-27

Applicant: ABBOTT LABORATORIES ,  CALDERWOOD, David J. ,  FRANK, Kristine E. ,  BETSCHMANN, Patrick ,  BREINLINGER, Eric C. ,  DIXON, Richard W.

Inventor： CALDERWOOD, David J. ,  FRANK, Kristine E. ,  BETSCHMANN, Patrick ,  BREINLINGER, Eric C. ,  DIXON, Richard W.

IPC: A01N43/58 ,  A61K31/50 ,  C07D471/00

CPC classification number: C07D487/04

Abstract: The present invention is directed to novel imidazopyrazine compounds useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Abstract translation: 本发明涉及用作激酶抑制剂的新颖的咪唑并嗪化合物，因此可用于治疗某些病症和疾病，特别是炎性病症和疾病以及增殖性病症和病症，例如癌症。

公开(公告)号：WO2008060621A3

公开(公告)日：2008-05-22

申请号：PCT/US2007/024076

申请日：2007-11-16

Applicant: ABBOTT LABORATORIES ,  GEORGE, Dawn M. ,  DIXON, Richard W. ,  FRIEDMAN, Michael ,  HOBSON, Adrian ,  LI, Biqin ,  WANG, Lu ,  WU, Xiaoyun ,  WISHART, Neil

Inventor： GEORGE, Dawn M. ,  DIXON, Richard W. ,  FRIEDMAN, Michael ,  HOBSON, Adrian ,  LI, Biqin ,  WANG, Lu ,  WU, Xiaoyun ,  WISHART, Neil

IPC: A61K31/445 ,  C07D211/00

Abstract: The present invention is directed to novel aminopyrrolidines of formula (I), pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

公开(公告)号：EP1907421A2

公开(公告)日：2008-04-09

申请号：EP06785967.8

申请日：2006-06-29

Applicant: ABBOTT LABORATORIES

Inventor： LACY, Susan E. ,  FUNG, Emma ,  BELK, Jonathan P. ,  DIXON, Richard W. ,  ROGUSKA, Michael ,  HINTON, Paul R. ,  KUMAR, Shankar

IPC: C07K14/715

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

公开(公告)号：EP2001480A2

公开(公告)日：2008-12-17

申请号：EP07754773.5

申请日：2007-04-02

Applicant: ABBOTT LABORATORIES

Inventor： ERICSSON, Anna M. ,  BURCHAT, Andrew ,  FRANK, Kristine E. ,  CALDERWOOD, David J. ,  ABBOTT, Lily K. ,  ARGIRIADI, Maria A. ,  BORHANI, David W. ,  CUSACK, Kevin P. ,  DIXON, Richard W. ,  GORDON, Thomas D. ,  MULLEN, Kelly D. ,  TALANIAN, Robert V. ,  WU, Xiaoyun ,  ZHANG, Xiaolei ,  WANG, Lu X. ,  LI, Biqin ,  BARBERIS, Claude E. ,  WISHART, Neil

IPC: A61K31/5377

CPC classification number: C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/04 ,  C07D409/14

Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Abstract translation: 式（I）的新化合物或其式（I）的药用盐，前药和生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。

公开(公告)号：EP2139329A1

公开(公告)日：2010-01-06

申请号：EP08742312.5

申请日：2008-03-27

Applicant: ABBOTT LABORATORIES

Inventor： CALDERWOOD, David J. ,  FRANK, Kristine E. ,  BETSCHMANN, Patrick ,  BREINLINGER, Eric C. ,  DIXON, Richard W.

IPC: A01N43/58 ,  A61K31/50 ,  C07D471/00

CPC classification number: C07D487/04

Abstract: The present invention is directed to novel imidazopyrazine compounds useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

公开(公告)号：EP2099454A2

公开(公告)日：2009-09-16

申请号：EP07867491.8

申请日：2007-11-16

Applicant: ABBOTT LABORATORIES

Inventor： GEORGE, Dawn M. ,  DIXON, Richard W. ,  FRIEDMAN, Michael ,  HOBSON, Adrian ,  LI, Biqin ,  WANG, Lu ,  WU, Xiaoyun ,  WISHART, Neil

IPC: A61K31/445 ,  C07D211/00

CPC classification number: A61K31/454 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4747 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D207/14 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D487/14

Abstract: The present invention is directed to novel aminopyrrolidines of formula (I), pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.